**Author details**

Gamal Abdul Hamid1 \* and Fadhel Hariri<sup>2</sup>

1 Faculty of Medicine, Aden University, Aden, Yemen

2 Ministry of Public Health, Aden, Yemen

\*Address all correspondence to: drgamal2000@yahoo.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**7**

*Introductory Chapter: Advances in Hematologic Malignancies*

[9] Serratì S, De Summa S, Pilato B, et al. Next-generation sequencing: Advances and applications in cancer diagnosis. OncoTargets and Therapy. 2016;**9**: 7355-7365. DOI: 10.2147/OTT.S99807

[10] Bacher U, Kohlmann A, Haferlach T. Perspectives of gene expression profiling

haematological malignancies. Briefings in Functional Genomics & Proteomics. 2009;**8**(3):184-193. DOI: 10.1093/bfgp/

[11] Gallipoli P, Giotopoulos G, Huntly BJ. Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Therapeutic Advances in Hematology. 2015;**6**(3):103-119. DOI:

for diagnosis and therapy in

elp011. Epub: May 27, 2009

10.1177/2040620715577614

July 24, 2017

[12] Burke MJ, Bhatla T. Epigenetic modifications in pediatric acute lymphoblastic leukemia. Frontiers in Pediatrics. 2014;**2**:42. DOI: 10.3389/ fped.2014.00042. eCollection 2014

[13] Charmsaz S, Scott AM, Boyd AW. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. Experimental Hematology. 2017;**54**:31-39. DOI: 10.1016/j.exphem.2017.07.003. Epub:

[14] Lohr JG, Stojanov P, Carter SL, Multiple Myeloma Research

10.1016/j.ccr.2013.12.015

[15] Harada H, Harada Y. Recent advances in myelodysplastic

syndromes: Molecular pathogenesis and its implications for targeted therapies. Cancer Science. 2015;**106**:329-336. DOI: 10.1111/ cas.12614. Epub: February 25, 2015

Consortium, et al. Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy. Cancer Cell. 2014;**25**:91-101. DOI:

*DOI: http://dx.doi.org/10.5772/intechopen.88777*

lymphoma: Why has survival improved? The Lancet Oncology. 2014;**15**:906-907. DOI: 10.1016/S1470-2045(14)70312-2

[3] Hamid GA. Pattern of hematological malignancies in Al-Gamhouria Teaching Hospital, Aden, Yemen 2008-2010. Turkish Journal of Hematology. 2012;**29**:342-347. DOI: 10.5505/

[4] Bowman RL, Busque L, Levine RL. Clonal hematopoiesis and evolution to hematopoietic malignancies. Cell Stem Cell. 2018;**22**(2):157-170. DOI: 10.1016/j.

[5] Braggio E, Egan JB, Fonseca R, et al. Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer Journal. 2013;**3**:e127. DOI: 10.1038/bcj.2013.26

[6] Prakash G, Kaur A, Malhotra P, et al. Current role of genetics in hematologic

[7] Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies.

2007;**44**:3823-3837. DOI: 10.1016/j.

[8] Wan TK. Molecular cytogenetics: Techniques, developments and applications. The Journal of Hong Kong Institute of Medical Laboratory Sciences. 2009-2010;**12**(1&2):1-12

malignancies. Indian Journal of Hematology and Blood Transfusion. 2016;**32**(1):18-31. DOI: 10.1007/s12288- 015-0584-4. Epub: September 16, 2015

Molecular Immunology.

molimm.2007.06.151

[2] Smith A, Howell D, Patmore R. Incidence of haematological malignancy

by sub-type: A report from the Haematological Malignancy Research Network. British Journal of Cancer. 2011;**105**(11):1684-1692. DOI: 10.1038/

[1] Munro AJ. Leukaemia and

**References**

bjc.2011.450

tjh.2012.0376

stem.2018.01.011

*Introductory Chapter: Advances in Hematologic Malignancies DOI: http://dx.doi.org/10.5772/intechopen.88777*
